|
P1: The role of CD49d expression in chronic lymphocytic leukemia cells
Csilla Tolnai-Kriston, Márk Plander, Ágnes Márk, Anna sebestyén, András Matolcsy, Gábor Barna
1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
P2: Effect of lenalidomide on viability and surface molecule expression of chronic lymphocytic leukemia (CLL) cells
Csilla Tolnai-Kriston, Márk Hernádfői, Ferenc Takács, András Matolcsy, Gábor Barna
1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest
P3: Convergence of somatic mutations within the JAK-STAT signalling pathway in a novel RUNX1-mutated pedigree
Kiran Tawana (1), Jun Wang (1), Péter Király (2,3), Dóra Marosvári (2,3), Krisztián Kállay (4), Gábor Benyó (4), Ahad el Seraihi (1), Gergely Kriván (4), Marianna Zombori (5), Attila Tordai (6), Judit Csomor (2), Jude Fitzgibbon (1), Csaba Bödör (2,3)
(1) Barts Cancer Institute, Centre for Haemato-Oncology, London, UK; (2) Semmelweis University, Department of Pathology and Experimental Cancer Research, Budapest, Hungary; (3) MTA-SE Lendulet Molecular Oncohematology Research Group; (4) Szt. László Hospital, Budapest, Hungary (5) Heim Pal Children Hospital, Budapest, Hungary; (6) National Blood Transfusion Institute, Budapest, Hungary
P4: The effect of microenvironmental factors on the development of myeloma cells
Gábor Barna (1), Ágnes Márk (1), Gergely Varga (2), Botond Timár (1), Csilla Kriston (1), Orsolya Szabó (1), Linda Deák (1), András Matolcsy (1)
(1) 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary (2) 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
P5: mTOR activity is reduced in PCNSL
Dóra Marosvári (1, 2), Noémi Nagy (1), Csilla Kriston (1), Beáta Deák (3), Zoltán Szállási (4, 5, 6) Anna Sebestyén (1, 7), Lilla Reiniger (1, 6)
(1): 1st Department of Pathology and Experimental Research, Semmelweis University, Budapest, Hungary;(2): MTA-SE Lendulet Molecular Oncohematology Research Group; (3): National Istitute of Oncology, Budapest, Hungary; (4): Children’s Hospital Informatics Program at the Harvard–Massachusetts Institute of Technology Division of Health Sciences and Technology, Harvard Medical School, Boston, MA, United States;(5): Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark; (6): 2nd Department of Pathology, MTA-SE NAP, Brain Metastasis Research Group, Hungarian Academy of Sciences, Semmelweis University, Budapest, Hungary; (7): Tumour Progression Research Group of Joint Research Organization of Hungarian Academy of Sciences, Semmelweis University, Budapest, Hungary
P6: The effects of mTORC1 inhibitor on IDH mutant cell line as a model system
Hujber Z, Petővári G, Nagy N, Dankó T, Krencz I, Szoboszlai N, Király PA, Borbély A, Jeney A, Sebestyén A
Semmelweis University, 1st Department of Pathology and Experimental Cancer Research
P7: Targeting the PI3K-AKT-mTOR signalling pathway to inhibit the tumour growth in Hodgkin Lymphoma cell lines
Noémi Nagy, Ágnes Márk, Zoltán Hujber, Gábor Petővári, Bach Krisztina, Titanilla Dankó, Ildikó Krencz, Anna Molnár, Melinda Hajdu, Anna Sebestyén
1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
P8: Pharmacogenetic analysis of toxic encephalopathy in pediatric acute lymphoblastic leukemia patients
J. C. Sági (1), N. Kutszegi (1), B. Egyed (2), A. Falus1, G. T. Kovács (2), C. Szalai (1,3), D. J. Erdélyi (2), Á. F. Semsei (1)
(1) Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest, Hungary (2) 2nd Department of Paediatrics, Semmelweis University, Budapest, Hungary (3) Heim Pal Children Hospital, Budapest, Hungary
P9: Altered MicroRNA Expression in Folliculotropic and Transformed Mycosis Fungoides
Dóra Marosvári (1,2) Vanda Téglási (1) Irén Csala (3) Márta Marschalkó (4) Judit Hársing (4) Csaba Bödör (1,2) Botond Timár (1), Judit Csomor (1) Lilla Reiniger (1,5)
(1) 1st Department of Pathology and Experimental Research, Semmelweis University, Budapest, Hungary (2) MTA-SE Lendulet Molecular Oncohematology Research Group (3) Institute of Behavioural Sciences, Semmelweis University, Budapest, Hungary (4) Department of Dermatovenerology and Dermatooncology, Semmelweis University, Budapest, Hungary (5) 2nd Department of Pathology, MTA-SE NAP, Brain Metastasis Research Group, Hungarian Academy of Sciences, Semmelweis University, Budapest, Hungary
P10: Interferon-gamma production based virus specific T cell detection by functional flow cytometry test after allogeneic haematopoetic stem cell transplantation
Tasnady Sz, Karaszi E, Hardi A, Szederjesi A, Bihari Gy, Krivan G, Reti M, Masszi T
United St Istvan and St Laszlo Hospital, Budapest, Hungary; Semmelweis University, Budapest, Hungary
P11: Metabolic characterization and detection of 2-hydroxyglutarate in different tumour samples
Gábor Petővári (1), Zoltán Hujber (1), Titanilla Dankó (1), Norbert Szoboszlai (2), Noémi Nagy (1), Ildikó Krencz (1), Péter A. Király (1,4), Regina Raffay (1), András Jeney (1), Anna Sebestyén (1,3)
(1) 1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary (2) Laboratory of Environmental Chemistry and Bioanalytics, Department of Analytical Chemistry, Institute of Chemistry, Eötvös Loránd University, Budapest, Hungary (3) Tumor Progression Research Group Joint Research Organization of Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary (4) Lendület Molecular Oncohematology Research Group of Hungarian Academy of Sciences, Semmelweis University, Budapest, Hungary
P12: Tumor-to-tumor metastasis: An initial manifestation of systemic disease
Hajnalka Rajnai, Lilla Reiniger
Semmelweis University, 1st Department of Pathology and Experimental Cancer Research
P13: In search of the molecular background of cyclic thrombocytopenia and thrombocytosis
Hajnes J, Szabó Diana Lili, Szili B, Bödör Cs,Nagy Zs, Demeter J
1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary
P14: The possibility of treatment free remission in a large multicentric chronic myeloid leukemia population in Hungary
Richard Kiss et al.
MTA-SE Lendulet Molecular Oncohematology Research Group, 1st Department of Pathology and Experimental Cancer Research, Budapest
P15: Cardiovascular aspects of chronic myeloid leukemia treated with tyrosine kinase inhibitors
Júlia Gaál-Weisinger, Orsolya Mucsi, Gábor Körösmezey, Balázs Szili, Ilona Tárkányi, Judit Csomor, Zsolt Nagy, Judit Demeter
1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary
P16: Variant allele frequency of JAK2 V617F and CALR mutations and their clinical significance in Philadelphia negative myeloproliferative neoplasms
Ambrus Gango et al.
MTA-SE Lendulet Molecular Oncohematology Research Group, 1st Department of Pathology and Experimental Cancer Research, Budapest
P17: Multiplex cutan B-cell lymphomas associated with angioimmunoblastic T-cell lymphoma – case report and review of the literature
Molnár Dávid (1), Gyöngyösi Nóra (2), Paksi Melinda (3), Demeter Judit (3), Kuroli Enikő (2), Marschalkó Márta (2), Csomor Judit (1), Matolcsy András (1), Szepesi Ágota (1)
(1) 1st Department of Pathology and Experimental Cancer Research, (2)Department of Dermatology, Venerology and Dermatooncology, (3) 1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary
P18: Actinomycosis- a diagnostic challenge 8 years after complete remission of diffuse large B cell lymphoma
Hanna Eid (1), Ildikó Istenes (1), Gabriella Győri (2), János Sinkó (3) Eszter Székely (4), Judit Demeter (1)
(1) Semmelweis University, 1st Department of Medicine (2) Semmelweis University, Department of Radiology (3) Department of Hematology and HSCT, United Szent István and Szent László Hospital (4) Semmelweis University, 2nd Department of Pathology and Experimental Cancer Research
P19: Treatment strategies and outcome of classical hairy cell leukemia (HCL) and HCL-variant differ due to differences in their molecular background
Sári E (1), Körösmezey G (1), Király P (1,2), Tárkányi I (1), Hanna E (1), Bödör Cs (2), Csomor J (2), Nagy Zs (1), Demeter J (1)
(1) Semmelweis University, 1st Department of Internal Medicine (2) MTA-SE Lendület Molecular Oncohematology Research Group
P20: Severe cold autoimmune hemolytic anaemia associated with Waldenström macroglobulinaemia: – longterm success of treatment with rituximab- CVP protocol
Ildikó Istenes (1), Judit Jakab (2) , Judit Csomor (3), Zsolt Nagy (1), Judit Demeter (1)
(1) Semmelweis University, 1st. Dept of Medicine (2) Hungarian National Blood Transfusion Service (3) Semmelweis University, 1st Dept of Pathology and Experimental Cancer Research
|